Pancreatic Cancer Research

ResearcherKyushu UniversityNo recent work listed

Hayato Fujita

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5037772281, A5112542552. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers · 2013: 2 papers · 2014: none · 2015: none · 2016: 3 papers

Papers 13

  1. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Co-author DOI 10.1111/cas.13024↗
  2. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Co-author DOI 10.3892/ijo.2016.3374↗
  3. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Co-author DOI 10.3892/ijo.2016.3389↗
  4. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318279bd66↗
  5. Kindlin-1 expression is involved in migration and invasion of pancreatic cancer. Co-author DOI 10.3892/ijo.2013.1838↗
  6. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02113.x↗
  7. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-011-1970-2↗
  8. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Co-author DOI 10.1016/j.surg.2011.06.017↗
  9. Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia. Co-author DOI 10.1111/j.1349-7006.2011.01936.x↗
  10. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Co-author DOI 10.1245/s10434-011-1602-x↗
  11. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fl… Co-author DOI 10.3892/ijo.2011.1058↗
  12. Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells. Co-author PMID 21508376↗
  13. [Molecular biology-based diagnosis and therapy for pancreatic cancer]. Co-author PMID 21823514↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenoki Ohuchida · 12 shared papers, 2011–2016 · strength 0.42
  2. Takao Ohtsuka · 8 shared papers, 2011–2016 · strength 0.30
  3. Masao Tanaka · 9 shared papers, 2011–2013 · strength 0.26
  4. Masafumi Nakamura · 4 shared papers, 2012–2016 · strength 0.18
  5. Yoshinao Oda · 3 shared papers, 2011–2016 · strength 0.13
  6. Ming Zhao · 4 shared papers, 2011–2013 · strength 0.12
  7. Biao Zheng · 2 shared papers, 2016 · strength 0.10
  8. Tadashi Kayashima · 4 shared papers, 2011–2012 · strength 0.10
  9. Yoshihiro Miyasaka · 2 shared papers, 2016 · strength 0.10
  10. Shingo Kozono · 3 shared papers, 2012–2013 · strength 0.10
  11. Naoki Ikenaga · 3 shared papers, 2011–2013 · strength 0.09
  12. Lin Cui · 3 shared papers, 2011 · strength 0.07
  13. Prawej Mahawithitwong · 2 shared papers, 2013 · strength 0.07
  14. Koji Shindo · 2 shared papers, 2013 · strength 0.07
  15. Kohei Horioka · 1 shared paper, 2016 · strength 0.05
  16. Takashi Okumura · 1 shared paper, 2016 · strength 0.05
  17. Masafumi Sada · 1 shared paper, 2016 · strength 0.05
  18. Masaki Yoshida · 1 shared paper, 2016 · strength 0.05
  19. Junji Ueda · 2 shared papers, 2011 · strength 0.05
  20. Yoshiro Chijiiwa · 1 shared paper, 2016 · strength 0.05
  21. Yusuke Mizuuchi · 1 shared paper, 2016 · strength 0.05
  22. Yoshinao Oda · 1 shared paper, 2016 · strength 0.05
  23. Kohei Nakata · 2 shared papers, 2011 · strength 0.05
  24. Kosuke Tsutsumi · 1 shared paper, 2012 · strength 0.03
  25. Makoto Hashizume · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.